These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2441046)

  • 1. Interferons and systemic lupus erythematosus.
    Bankhurst AD
    J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():63-7. PubMed ID: 2441046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal macrophages and NK cell cytotoxicity in human systemic lupus erythematosus and the role of interferon and serum factors.
    Zippel D; Lackovic V; Kocisková D; Rovenský J; Borecký L; Stelzner A
    Acta Virol; 1989 Sep; 33(5):447-53. PubMed ID: 2483602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon and natural killer cells in systemic lupus erythematosus.
    Strannegård O; Hermodsson S; Westberg G
    Clin Exp Immunol; 1982 Nov; 50(2):246-52. PubMed ID: 6185256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.
    Green MR; Kennell AS; Larche MJ; Seifert MH; Isenberg DA; Salaman MR
    Clin Exp Immunol; 2005 Jul; 141(1):165-73. PubMed ID: 15958083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of natural killing with antibody dependent cell mediated cytotoxicity in patients with systemic lupus erythematosus.
    Kozlowski SH; Hirsen DJ; Jackson EJ
    J Rheumatol; 1982; 9(1):59-62. PubMed ID: 7086780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cells and interferon responses in patients with systemic lupus erythematosus.
    Tsokos GC; Rook AH; Djeu JY; Balow JE
    Clin Exp Immunol; 1982 Nov; 50(2):239-45. PubMed ID: 6817954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective natural killer (NK) and killer (K) cell function in systemic lupus erythematosus.
    Ewan PW; Barrett HM; Pusey CD
    J Clin Lab Immunol; 1983 Feb; 10(2):71-6. PubMed ID: 6842577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal natural killer cell activity in systemic lupus erythematosus: an intrinsic defect in the lytic event.
    Katz P; Zaytoun AM; Lee JH; Panush RS; Longley S
    J Immunol; 1982 Nov; 129(5):1966-71. PubMed ID: 7119439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibody-dependent and natural cellular cytotoxic reactions in rheumatic diseases].
    Aleksandrova EN; Zimin IuI; Nasonov EL
    Ter Arkh; 1984; 56(10):130-6. PubMed ID: 6084315
    [No Abstract]   [Full Text] [Related]  

  • 10. Insensitivity to interferon of NK cells from patients with systemic lupus erythematosus.
    Fitzharris P; Alcocer J; Stephens HA; Knight RA; Snaith ML
    Clin Exp Immunol; 1982 Jan; 47(1):110-8. PubMed ID: 6178542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of serum interferon with some clinical and humoral signs of systemic lupus erythematosus.
    Matei I; Ghyka G; Savi I; Tudor A
    Med Interne; 1990; 28(4):289-94. PubMed ID: 1713346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic lupus erythematosus: all roads lead to type I interferons.
    Pascual V; Farkas L; Banchereau J
    Curr Opin Immunol; 2006 Dec; 18(6):676-82. PubMed ID: 17011763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon inhibitor in the blood of patients with systemic lupus erythematosus.
    Chadha KC; Ambrus JL; Stadler I; Ambrus JL
    J Biol Regul Homeost Agents; 1991; 5(1):1-9. PubMed ID: 1715634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF).
    Wright SC; Bonavida B
    J Immunol; 1983 Jun; 130(6):2965-8. PubMed ID: 6189909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oral lesions in systemic lupus erythematosus. I. The etiopathogenic aspects of lupus erythematosus].
    Bonaccorso A; Tripi TR
    Minerva Stomatol; 1998; 47(1-2):27-31. PubMed ID: 9578644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular immunity in systemic lupus erythematosus.
    Boumpas DT; Eleftheriades EG; Tsokos GC
    In Vivo; 1988; 2(1):41-5. PubMed ID: 2979815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic lupus erythematosus. Some contemporary laboratory aspects.
    Deegan MJ
    Arch Pathol Lab Med; 1980 Aug; 104(8):399-404. PubMed ID: 6967303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between circulating interferon and anti-interferon antibodies and impaired natural killer cell activity in systemic lupus erythematosus.
    Sibbitt WL; Gibbs DL; Kenny C; Bankhurst AD; Searles RP; Ley KD
    Arthritis Rheum; 1985 Jun; 28(6):624-9. PubMed ID: 2408630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of immune abnormalities in systemic lupus erythematosus.
    Steinberg AD; Smith HR; Laskin CA; Steinberg BJ; Smolen JS
    Am J Kidney Dis; 1982 Jul; 2(1 Suppl 1):101-10. PubMed ID: 6213146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha 1-fetoprotein--relation to impaired macrophage function in systemic lupus erythematosus?
    Wollina U
    Dermatol Monatsschr; 1984; 170(11):703-4. PubMed ID: 6083887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.